| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454132 | Lung Cancer | 2018 | 5 Pages |
Abstract
ICIs improve survival in previously treated advanced NSCLC patients across PD-L1 expression levels compared to docetaxel. There is a positive dose-response relationship between PD-L1 expression and survival benefits, and little evidence of survival differences between nivolumab, pembrolizumab and atezolizumab.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Pui San Tan, Pedro Jr., Benjamin Haaland, Gilberto Lopes,